Core Laboratories Inc.
CLB
$13.15
-$0.03-0.23%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 29.03M | 29.67M | 32.12M | 29.63M | 28.03M |
| Total Depreciation and Amortization | 14.70M | 14.65M | 14.65M | 14.73M | 14.83M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.07M | 7.91M | -1.71M | 1.83M | -588.00K |
| Change in Net Operating Assets | -13.47M | -15.20M | 4.65M | 8.10M | 15.25M |
| Cash from Operations | 34.34M | 37.03M | 49.70M | 54.30M | 57.52M |
| Capital Expenditure | -15.90M | -14.59M | -15.32M | -15.02M | -13.56M |
| Sale of Property, Plant, and Equipment | 3.28M | 3.02M | 3.15M | 3.13M | 2.37M |
| Cash Acquisitions | -1.24M | -1.24M | -617.00K | -617.00K | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 7.47M | 10.58M | 10.75M | 7.58M | 7.22M |
| Cash from Investing | -6.39M | -2.23M | -2.04M | -4.92M | -3.97M |
| Total Debt Issued | 101.00M | 48.00M | 42.00M | 47.00M | 43.00M |
| Total Debt Repaid | -110.00M | -63.00M | -67.00M | -71.00M | -80.00M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -14.40M | -12.43M | -14.67M | -9.86M | -7.28M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.86M | -1.87M | -1.87M | -1.88M | -1.88M |
| Other Financing Activities | -1.97M | -1.96M | -1.96M | -143.00K | -198.00K |
| Cash from Financing | -27.23M | -31.26M | -43.51M | -35.88M | -46.36M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 712.00K | 3.55M | 4.16M | 13.49M | 7.19M |